Press releases

Guard Therapeutics International AB (publ) today announces that a Nomination Committee has been appointed in accordance with previous AGM resolutions.

Guard Therapeutics (publ) (“Guard” or the “Company”) announces today that Redeye Aktiebolag (“Redeye”) has been appointed as financial advisor in connection with the strategic review announced by the Company in its press release dated 4 December 2025. The review includes an assessment of potential strategic alternatives, including...

Guard Therapeutics (publ) has entered into an agreement with Redeye AB regarding the service as Certified Adviser. Redeye AB will assume the role of Certified Adviser on 8 December 2025.

Guard Therapeutics (publ) (“Guard” or the “Company”) today announces that the Board of Directors has resolved to commence an exploratory process regarding strategic alternatives, including identifying potential candidates for a merger or reverse takeover (RTO) of the Company. Guard believes that its listing on Nasdaq First North Growth...

Guard Therapeutics (public) (“Guard” or “the Company”) today provides an assessment of the full results from the Phase 2b POINTER study evaluating RMC-035 in patients undergoing open-heart surgery. As previously communicated, the study did not meet its primary or key secondary efficacy endpoints, although promising signals were observed...